Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | HPD | P32754 | 2/20 | 0.46 |
| ▸ | MGMT | P16455 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.43 |
| ▸ | CTSV | O60911 | 1/20 | 0.43 |
| ▸ | CTSL | P07711 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | CYP19A1 | P11511 | 4/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.42 |
| ▸ | PPIA | P62937 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30318890 | 1.00 | MAPT (0.46) | MAPTMEN1KMT2AHPDMGMT | |
| SCHEMBL3614237 | 0.83 | MAPT (0.49) | MAPTMEN1KMT2AHPDMGMT | |
| SCHEMBL31285352 | 0.83 | MAPT (0.46) | MAPTMEN1KMT2AHPDMGMT | |
| SCHEMBL28231949 | 0.81 | HPD (0.51) | MAPTMEN1KMT2AHPDMGMT | |
| SCHEMBL27750368 | 0.81 | RAB9A (0.45) | MAPTMEN1KMT2AHPDMGMT | |
| SCHEMBL23886681 | 0.81 | MAPT (0.46) | MAPTMEN1KMT2AHPDMGMT | |
| SCHEMBL31448596 | 0.81 | MAPT (0.46) | MAPTMEN1KMT2AHPDMGMT | |
| SCHEMBL1559731 | 0.80 | MAPT (0.66) | MAPTMEN1KMT2AHPDSMN1; SMN2 | |
| SCHEMBL1559732 | 0.79 | MAPT (0.43) | MAPTMEN1KMT2AHPDMGMT | |
| SCHEMBL27739041 | 0.79 | CTSV (0.49) | MAPTMEN1KMT2AMGMTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12239643-B2 | Therapeutic agent for inflammatory diseases, autoimmune diseases, fibrotic diseases, and cancer diseases | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2025-03-04 | — | — | US | disclosed |
| US-20240309010-A1 | METHOD FOR PRODUCING BENZOXAZOLE DERIVATIVE HAVING BICYCLIC PIPERAZINE RING OR SALT THEREOF, AND METHOD FOR PRODUCING MATERIAL THEREOF | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2024-09-19 | — | — | US | disclosed |
| EP-4365174-A1 | METHOD FOR PRODUCING BENZOXAZOLE DERIVATIVE HAVING BICYCLIC PIPERAZINE RING OR SALT THEREOF, AND METHOD FOR PRODUCING MATERIAL THEREOF | Meiji Seika Pharma Co., Ltd. (JP) | 2024-05-08 | — | — | EP | disclosed |
| CN-112351986-B | Crystals of benzoxazole derivative | 明治制果药业株式会社 | 2023-04-18 | — | — | CN | disclosed |
| US-11512091-B2 | Crystal of benzoxazole derivative | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2022-11-29 | — | — | US | disclosed |
| EP-3816167-B1 | CRYSTAL OF A BENZOXAZOLE DERIVATIVE | MEIJI SEIKA PHARMA CO LTD (JP) | 2022-08-03 | — | — | EP | disclosed |
| CN-110114358-B | Novel compound and pharmacologically acceptable salt thereof | 明治制果药业株式会社 | 2021-12-03 | — | — | CN | disclosed |
| US-20210315892-A1 | THERAPEUTIC AGENT FOR INFLAMMATORY DISEASES, AUTOIMMUNE DISEASES, FIBROTIC DISEASES, AND CANCER DISEASES | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2021-10-14 | — | — | US | disclosed |
| EP-3560925-B1 | NOVEL COMPOUND AND PHARMACEUTICALLY-ACCEPTABLE SALT THEREOF | MEIJI SEIKA PHARMA CO LTD (JP) | 2021-06-02 | — | — | EP | disclosed |
| US-20210155630-A1 | CRYSTAL OF BENZOXAZOLE DERIVATIVE | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2021-05-27 | — | — | US | disclosed |
| EP-3816167-A1 | CRYSTAL OF BENZOXAZOLE DERIVATIVE | Meiji Seika Pharma Co., Ltd. (JP) | 2021-05-05 | — | — | EP | disclosed |
| EP-3815687-A1 | THERAPEUTIC AGENT FOR INFLAMMATORY DISEASES, AUTOIMMUNE DISEASES, FIBROTIC DISEASES, AND CANCER DISEASES | Meiji Seika Pharma Co., Ltd. (JP) | 2021-05-05 | — | — | EP | disclosed |
| CN-112312914-A | Therapeutic agent for inflammatory disease, autoimmune disease, fibrotic disease, and cancer disease | 明治制果药业株式会社 | 2021-02-02 | — | — | CN | disclosed |
| US-10669283-B2 | Compound and pharmacologically acceptable salt thereof | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2020-06-02 | — | — | US | disclosed |
| WO-2020004521-A1 | THERAPEUTIC AGENT FOR INFLAMMATORY DISEASES, AUTOIMMUNE DISEASES, FIBROTIC DISEASES, AND CANCER DISEASES | Ｍｅｉｊｉ Ｓｅｉｋａファルマ株式会社 | 2020-01-02 | — | — | WO | disclosed |
| EP-3560925-A1 | NOVEL COMPOUND AND PHARMACEUTICALLY-ACCEPTABLE SALT THEREOF | Meiji Seika Pharma Co., Ltd. (JP) | 2019-10-30 | — | — | EP | disclosed |
| US-20190322686-A1 | NOVEL COMPOUND AND PHARMACOLOGICALLY ACCEPTABLE SALT THEREOF | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2019-10-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190322686-A1 | NOVEL COMPOUND AND PHARMACOLOGICALLY ACCEPTABLE SALT THEREOF | REN, CYP11B1, CYP11B2 | MAPT 3939/4885MEN1 2096/4885KMT2A 2420/4885 |
| US-10669283-B2 | Compound and pharmacologically acceptable salt thereof | REN, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CYP11B2 | MAPT 3178/4885MEN1 1081/4885KMT2A 2308/4885 |
| US-20210155630-A1 | CRYSTAL OF BENZOXAZOLE DERIVATIVE | OXA1L, XDH, CYP4X1 | MAPT 2302/4885MEN1 2564/4885KMT2A 2293/4885 |
| US-20240309010-A1 | METHOD FOR PRODUCING BENZOXAZOLE DERIVATIVE HAVING BICYCLIC PIPERAZINE RING OR SALT THEREOF, AND METHOD FOR PRODUCING MATERIAL THEREOF | BAZ2B, JAK2, BRIX1 | MAPT 3984/4885MEN1 2547/4885KMT2A 1116/4885 |
| US-11512091-B2 | Crystal of benzoxazole derivative | OXA1L, XDH, CYP4X1 | MAPT 2302/4885MEN1 2564/4885KMT2A 2293/4885 |
| US-20210315892-A1 | THERAPEUTIC AGENT FOR INFLAMMATORY DISEASES, AUTOIMMUNE DISEASES, FIBROTIC DISEASES, AND CANCER DISEASES | CCR1, SSB, C5 | MAPT 4782/4885MEN1 2779/4885KMT2A 2306/4885 |
| US-12239643-B2 | Therapeutic agent for inflammatory diseases, autoimmune diseases, fibrotic diseases, and cancer diseases | CCR1, SSB, C5 | MAPT 4782/4885MEN1 2779/4885KMT2A 2306/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.